Lyell immunopharma reports dose-dependent clinical activity from phase 1 trial of lyl797, a ror1-targeted car-t cell product candidate enhanced with its proprietary anti-exhaustion technology

South san francisco, calif., june 26, 2024 (globe newswire) -- lyell immunopharma, inc. (nasdaq: lyel), a clinical‑stage t-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced initial clinical and translational data from its phase 1 trial of lyl797, its first-generation reprogrammed ror1 car t‑cell product candidate enhanced with proprietary anti-exhaustion technology. the initial dataset consists primarily of patients with triple-negative breast cancer (tnbc) and demonstrated dose-dependent antitumor clinical activity and the ability of lyl797 car t cells to proliferate, infiltrate tumors and kill cancer cells in patients with relapsed/refractory disease. patients with tnbc treated with lyl797 had an objective response rate (orr) of 40% and clinical benefit rate (cbr) of 60% at the 150 x 106 car t cell dose level, with a cbr of 38% across all dose levels evaluable to date. common treatment-related adverse events in patients without lung metastases included grade 1 and 2 cytokine release syndrome (crs) and headache, and the expected cytopenia from lymphodepletion. there were no reports of immune effector cell-associated neurotoxicity syndrome (icans) attributed to lyl797. pneumonitis occurred in patients with lung metastases and dose escalation is continuing separately and more gradually in those patients. no dose-limiting toxicities have been reported in patients without lung involvement. all patients are now receiving prophylactic steroids prior to lyl797 treatment.
CAR Ratings Summary
CAR Quant Ranking